Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
- PMID:32783116
- DOI: 10.1007/s40263-020-00752-2
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
Abstract
Schizophrenia is a major mental illness associated with profound disability. Current treatments for schizophrenia (antipsychotics) all have a similar mechanism of action and are primarily dopamine type 2 receptor (D2R) antagonists. Antipsychotics are not fully effective for the majority of schizophrenia patients, suggesting the need for alternative approaches. The primary focus of this review is to assess the evidence for the role of the serotonin type 2A receptor (5-HT2AR) in schizophrenia. Topics include an overview of 5-HT2AR physiology and pathophysiology in schizophrenia, 5-HT2AR interaction with other neurotransmitter systems, including the glutamatergic system, a review of the 5-HT2AR/d-lysergic acid diethylamide (LSD) model of schizophrenia, a contrast of the 5-HT2AR and glutamatergic models of schizophrenia, and finally, a review of Food and Drug Administration (FDA)-approved and investigational 5-HT2AR-modulating compounds. Recent studies with lumeteperone, pimavanserin, and roluperidone are highlighted.
Similar articles
- Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Gαi1- and neutral antagonism for Gαq/11-proteins in human brain cortex.Muneta-Arrate I, Diez-Alarcia R, Horrillo I, Meana JJ.Muneta-Arrate I, et al.Eur Neuropsychopharmacol. 2020 Jul;36:83-89. doi: 10.1016/j.euroneuro.2020.05.004. Epub 2020 Jun 7.Eur Neuropsychopharmacol. 2020.PMID:32517960
- Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K.Borroto-Escuela DO, et al.Biochem Biophys Res Commun. 2014 Jan 3;443(1):278-84. doi: 10.1016/j.bbrc.2013.11.104. Epub 2013 Dec 2.Biochem Biophys Res Commun. 2014.PMID:24309097
- The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.Jalal B.Jalal B.Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091. doi: 10.1007/s00213-018-5042-1. Epub 2018 Oct 5.Psychopharmacology (Berl). 2018.PMID:30288594Free PMC article.Review.
- Serotonin 5-HT1A, 5-HT2A and dopamine D2 receptors strongly influence prefronto-hippocampal neural networks in alert mice: Contribution to the actions of risperidone.Gener T, Tauste Campo A, Alemany-González M, Nebot P, Delgado-Sallent C, Chanovas J, Puig MV.Gener T, et al.Neuropharmacology. 2019 Nov 1;158:107743. doi: 10.1016/j.neuropharm.2019.107743. Epub 2019 Aug 17.Neuropharmacology. 2019.PMID:31430459
- ACS chemical neuroscience molecule spotlight on Fanapt.Hopkins CR.Hopkins CR.ACS Chem Neurosci. 2010 Jun 16;1(6):410. doi: 10.1021/cn100024g.ACS Chem Neurosci. 2010.PMID:22778835Free PMC article.Review.
Cited by
- New Developments in the Treatment of Schizophrenia: An Expert Roundtable.Kantrowitz JT, Correll CU, Jain R, Cutler AJ.Kantrowitz JT, et al.Int J Neuropsychopharmacol. 2023 May 31;26(5):322-330. doi: 10.1093/ijnp/pyad011.Int J Neuropsychopharmacol. 2023.PMID:36932673Free PMC article.
- Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.Veselinović T, Neuner I.Veselinović T, et al.CNS Drugs. 2022 Aug;36(8):819-858. doi: 10.1007/s40263-022-00935-z. Epub 2022 Jul 13.CNS Drugs. 2022.PMID:35831706Free PMC article.Review.
- Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.Kantrowitz JT.Kantrowitz JT.CNS Drugs. 2021 Nov;35(11):1153-1161. doi: 10.1007/s40263-021-00864-3. Epub 2021 Oct 15.CNS Drugs. 2021.PMID:34655036Review.
- Pharmacological Treatment for Social Cognition: Current Evidence.Riccardi C, Montemagni C, Del Favero E, Bellino S, Brasso C, Rocca P.Riccardi C, et al.Int J Mol Sci. 2021 Jul 12;22(14):7457. doi: 10.3390/ijms22147457.Int J Mol Sci. 2021.PMID:34299076Free PMC article.Review.
- DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects.Kitaichi M, Kato T, Oki H, Tatara A, Kawada T, Miyazaki K, Ishikawa C, Kaneda K, Shimizu I.Kitaichi M, et al.Psychopharmacology (Berl). 2024 Nov;241(11):2223-2239. doi: 10.1007/s00213-024-06629-2. Epub 2024 Jun 10.Psychopharmacology (Berl). 2024.PMID:38856765
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical